Pasithea has announced the commencement of a Phase I/Ib open-label trial of PAS-004 for treating adults with ...

ADC Therapeutics has pulled the drug candidate from development, leaving it with one remaining clinical asset.

Nuvig Therapeutics has dosed the first subject in its Phase II INVGOR trial of NVG-2089 for individuals with CIDP.

BridgeBio Pharma has dosed the first subject in the ACT-EARLY study of acoramidis, a drug intended to prevent transthyretin ...

This follows what appeared to be a generally positive data readout for belrestotug at ESMO 2024 just a few months ago.

Roche has reported overall survival outcomes from a Phase III trial of Perjeta with Herceptin and chemotherapy in early-stage ...

People with bipolar disorder (BD) who have experienced childhood trauma (CT) will frequently document having more depressive ...

Connect Biopharma has begun a Phase II trial to assess rademikibart for treating acute exacerbations of asthma and type II ...

The human immunodeficiency virus (HIV) market across the seven major markets (7MM), comprising the US, France, Germany, Italy ...

GSK has reported positive outcomes from the Phase III GLISTEN trial of linerixibat for cholestatic pruritus (itch) and PBC.

Analysis suggests that air pollution exposure, while showing a more modest positive correlation with new Parkinson’s diagnoses than genetic risk, does increase the odds of its onset. Credit: ESB ...

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...